Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Pharmaceutical Buys Stake In Antitumor Firm

This article was originally published in PharmAsia News

Executive Summary

Simcere Pharmaceutical has announced that it is paying 64.82 million yuan ($9.2 million) to buy 70 percent stake in Anhui Zhongren Pharmaceutical, its third acquisition since listing in the U.S. last year. Anhui Zhongren specializes in the production of antitumor implant agents and is the developer of an innovative sustained-release fluorouracil implant that is unique in the market. One of Simcere's key strategies is to concentrate on core product acquisition and expansion; its latest purchase will enrich the firm's antitumor product portfolio as well as consolidate its leading position in the field. Company officials disclosed that some 800 million yuan ($114 million) has been allocated for future acquisitions. (Click here for more - Chinese language)

You may also be interested in...



ConMed’s Ortho Franchise Prioritizes Pipeline Over External Growth

ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.

Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac

Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.

Leading Medtechs See Organic Growth Across A Market In Flux

In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.

UsernamePublicRestriction

Register

SC068627

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel